Belgian giant InBev (INBVF.PK) is weighing an unsolicited bid for Anheuser-Busch Companies (BUD), according to people familiar with the matter. Industry analysts say an offer likely would top $45 billion, making it the largest beer acquisition ever: WSJ. Deutsche Bank reportedly downgrades BUD to hold from buy.
Zymogenetics (ZGEN) announces that the FDA approved a Prior Approval Supplement application for a 20,000 international unit (IU) vial of RECOTHROM Thrombin, topical (Recombinant) and also approved co-packaging of the 20,000-IU vial with the ZymoGenetics Spray Applicator Kit.
Flotek Industries (FTK) cuts $1.50-$1.60 2008 EPS forecast to $1.12-$1.22, citing first quarter performance which is below management's estimates and other factors.
Pediatrix Medical Group (PDX) sees $0.77-$0.80 second quarter EPS if neonatal intensive care unit (NICU) patient volume (down approximately 2% through the first 6 weeks of the quarter) remains at current levels for the rest of the period. In addition, at this time, doesn't expect to meet its previously issued 2008 EPS guidance, as a result of lower NICU patient volume during 2008 to date. Sets $100 million stock buyback.
Louisiana-Pacific (LPX) says it has adopted a new stockholder rights plan. The plan is not intended to deter offers that are fair and otherwise in the best interest of the Company's stockholders.